<DOC>
	<DOCNO>NCT02660034</DOCNO>
	<brief_summary>The Safety , Pharmacokinetics Antitumor Activity Anti-PD-1 Monoclonal Antibody BGB-A317 Combination With PARP Inhibitor BGB-290 Subjects With Advanced Solid Tumors</brief_summary>
	<brief_title>The Safety , Pharmacokinetics Antitumor Activity BGB-A317 Combination With BGB-290 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Subjects voluntarily agree participate give write informed consent . 2 . Subjects advance tumor fail least 1 prior chemotherapy . 3 . In Part A , subject must histologically cytologically confirm advanced tumor . 4 . In Part B , subject recruit one four expansion arm must histologically cytologically confirm advanced solid tumor BRCA1/2 mutation document HR MMR deficiency . 5 . Subjects must measurable disease define per RECIST version 1.1 . 6 . Male female ≥ 18 year age day sign informed consent . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 1 . 8 . Life expectancy ≥ 12 week . 9 . Subject must adequate organ function indicate follow laboratory value . 1 . Absolute neutrophil count ( ANC ) ≥ 1,500/mL 2 . Platelets ≥ 100,000/mL 3 . Hemoglobin ≥ 9 g/dL ≥ 5.6 mmol/L 4 . Serum creatinine ≤ 1.5 × upper limit normal ( ULN ) 5 . Serum total bilirubin ≤ 1.5 × ULN ( On fractionation ≤ 90 % total bilirubin unconjugated ) . 6 . Aspartate aminotransferase ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( serum glutamic pyruvic transaminase [ SGPT ] ) ≤ 2.5 × ULN ≤ 5 × ULN subject liver metastases 7. International normalize ratio ( INR ) prothrombin time ( PT ) ≤ 1.5 × ULN 8 . Activated partial thromboplastin time ( aPTT ) ≤ 1.5 × ULN 10 . Female subject eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) 2 . Childbearing potential , negative serum pregnancy test screening ( within 7 day first investigational product administration ) , breast feeding , use adequate contraception study entry throughout study 90 day last investigational product administration . 11 . Male subject eligible enter participate study vasectomize agree use contraception study treatment period least 180 day last dose study drug . 1 . History severe hypersensitivity reaction monoclonal antibody ( mAbs ) 2 . Prior malignancy within previous 2 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix breast 3 . Prior therapy target PD1 , program deathligand 1 ( PDL1 ) , PARP 4 . Subjects active autoimmune disease history autoimmune disease exclude ; 5 . Subjects exclude condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration . 6 . Has history interstitial lung disease noninfectious pneumonitis except induced radiation therapy . 7 . Known history human immunodeficiency virus ( HIV ) ; 8 . Active infection require therapy , positive test hepatitis B surface antigen ( HBsAg ) hepatitis C ribonucleic acid ( RNA ) ; 9 . Underlying medical condition , investigator 's opinion , make administration study drug hazardous obscure interpretation toxicity determination adverse event ( AEs ) ; 10 . Inability swallow oral medication ( capsule tablet ) without chew , break , crush , open otherwise alter product formulation . 11 . Prior chemotherapy , radiotherapy , immunotherapy investigational therapy use control cancer must complete least 4 week least 5 halflives ( whichever short ) study drug administration , AEs either return baseline stabilize . 12 . Use vaccine ( e.g. , infectious disease influenza varicella ) within 4 week ( 28 day ) initiation study therapy 60 day last administration study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dose Escalation</keyword>
	<keyword>Dose Expansion</keyword>
	<keyword>BGB-A317</keyword>
	<keyword>BGB-290</keyword>
</DOC>